MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/children11101164

Медицинская библиотека · Children (Basel, Switzerland) · 2024

Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.

Kavaz Tufan Asli, Ozak Batibay Fatma, Kaya Aksoy Gulsah, Gulhan Bora, Demircioglu Kilic Beltinge, Dursun Ismail, Buyukkaragoz Bahar, Caltik Yilmaz Aysun, Nalcacioglu Hulya, Becerir Tulay, Cetin Nuran, Celegen Kubra, Dinleyici Meltem, Kaya Mucahit, Kilic Omer, Dinleyici Ener Cagri

СтатьяПеревод в очереди

Аннотация

BACKGROUND/

OBJECTIVES

Eculizumab is a first-line treatment for atypical hemolytic uremic syndrome (aHUS), and patients undergoing eculizumab therapy may become more susceptible to infection caused by Neisseria meningitidis (Nm). While meningococcal vaccination is required for patients undergoing eculizumab therapy, there is limited knowledge about meningococcal carriage in children with aHUS. We aimed to evaluate (1) the prevalence of Nm carriage, (2) serogroup distribution, and (3) the immunization status of children undergoing eculizumab treatment for aHUS.

METHODS

The Meningo-aHUS study is a prospective, multi-center study evaluating meningococcal carriage in children and adolescents in Türkiye receiving eculizumab for aHUS. We noted the age, gender, daycare, school, or university attendance, passive smoking status, previous infection and antibiotic use, and previous immunization history, including meningococcal vaccines, from the medical records of those children with aHUS. We collected nasopharyngeal samples, tested them for Nm using real-time polymerase chain reaction, and performed a serogroup analysis on the positive samples.

RESULTS

We collected nasopharyngeal samples from 62 children with aHUS. Out of 62 children, 61 (98.4%) had received at least one dose of the meningococcal vaccine. The median time since the last meningococcal vaccine dose was 15 months (1-59 months). We detected meningococcal carriage in three (4.8%, 95% CI 1.0-13.5) children, and all three strains were non-groupable (NG). No other serogroups were detected.

CONCLUSIONS

Almost all the children received their risk-group meningococcal immunization, including booster doses. A 4.8% of children with aHUS carried NG meningococci and, no vaccine serogroups were detected. Patients treated with eculizumab remain profoundly susceptible to IMD due to these NG meningococcal strains. The occurrence of breakthrough cases and carriage of Nm, especially NG strains, highlights the significance of maintaining a state of constant alertness, promptly seeking medical attention, and swiftly treating any symptoms that align with IMD, regardless of their vaccination status or antibiotic prophylaxis.

Для цитирования: Kavaz Tufan Asli, Ozak Batibay Fatma, Kaya Aksoy Gulsah, Gulhan Bora, Demircioglu Kilic Beltinge, Dursun Ismail, Buyukkaragoz Bahar, Caltik Yilmaz Aysun, Nalcacioglu Hulya, Becerir Tulay, Cetin Nuran, Celegen Kubra, Dinleyici Meltem, Kaya Mucahit, Kilic Omer, Dinleyici Ener Cagri. Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.. Children (Basel, Switzerland). 2024. DOI: 10.3390/children11101164.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.